Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Rises By 7,330.0%

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 148,600 shares, an increase of 7,330.0% from the November 30th total of 2,000 shares. Based on an average daily trading volume, of 46,900 shares, the short-interest ratio is presently 3.2 days. Approximately 1.8% of the shares of the company are sold short.

Alterity Therapeutics Trading Up 20.4 %

Shares of ATHE stock traded up $0.50 during trading hours on Thursday, hitting $2.95. 70,273 shares of the company were exchanged, compared to its average volume of 50,163. Alterity Therapeutics has a 1 year low of $1.00 and a 1 year high of $3.19. The firm has a fifty day moving average of $1.52 and a 200 day moving average of $1.53.

Wall Street Analysts Forecast Growth

Separately, Maxim Group assumed coverage on Alterity Therapeutics in a report on Thursday, December 12th. They issued a “buy” rating and a $8.00 price objective on the stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.